1264 Recognition and management of immunotherapy toxicity: a quality improvement project

Le résumé fourni par la source

Background Immune checkpoint inhibitors (ICIs) have changed the landscape of cancer treatment over the past decade. With broaden ICIs use, internal medicine physicians are increasingly encountering them. Our study aims to assess Internal Medicine Resident’s (IMR) knowledge on immune related adverse events irAEs and identify potential gaps Methods We designed 21-questions pre-intervention survey in January 2022 assessing IMR knowledge of ICIs and associated irAEs. It assessed the following components regarding ICIs and irAEs: (1) recognition of ICIs, (2) recognition of organ systems associated with irAEs, (3) common timeframe of irAEs, (4) initial management strategies for irAEs, (5) common misconceptions about irAEs, and (6) self-rated physician comfort level on recognition/treatment of irAE. Teaching sessions by medical oncology attending and QI project team residents were conducted after survey. 21-questions post-intervention survey was sent to IMR in September 2022. The results of the surveys were compared. Results 42 of 57IMRs (73.7%) participated in pre-intervention survey and 45 of 57IMRs (78.9%) participated in post-intervention survey (tables 1 and 2). Limitations: The length of the survey limited our ability to test regarding a wide variety of ICIs and irAEs. Conclusions We identified the knowledge gaps regarding ICIs and irAEs among IMRs. Educational content provided in multiple formats demonstrated increased knowledge. IMRs may benefit from web-based learning tools and algorithms on ICIs/irAEs management.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.